All In Biotech

Drug Trial Radar · NCT05509023

Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Proof-of-Concept Study Evaluating the Safety and Efficacy of ADX-914 in Subjects With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Oct 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

102

Planned (sponsor's estimate)

Start

Sep 30, 2022

Primary completion

Dec 2024

Study completion Dec 2024

Sponsor

Lead sponsor
Q32 Bio Inc.Industry
Sponsor type
Industry
First posted
Aug 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atopic Dermatitis.

Conditions

  • Atopic Dermatitis

Interventions

  • ADX-914Drug

    Subcutaneous administration of ADX-914

  • PlaceboDrug

    Subcutaneous administration of Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A only: Safety parameters including incidence of serious adverse events and adverse events of special interestTime frame: 14 Weeks
  2. Part A and B: Mean percentage change from baseline in Eczema Area and Severity Index (EASI) score at Week 14 for ADX-914 vs placeboTime frame: 14 Weeks

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Cahaba Dermatology Skin Health Center

    Birmingham, Alabama

  • First OC Dermatology

    Fountain Valley, California

  • California Allergy and Asthma Medical Group- Los Angeles

    Los Angeles, California

  • Integrative Skin Science and Research

    Sacramento, California

  • Dermatology Institute and Skin Care Center

    Santa Monica, California

  • Torrance Clinical Research Institute Inc.

    Torrance, California

  • Integrated Research of Inland, Inc.

    Upland, California

  • RM Medical Research Inc.

    Homestead, Florida

  • Medical Research Center of Miami

    Miami, Florida

  • Well Pharma Medical Research Corporation

    Miami, Florida

  • GCP Research

    St. Petersburg, Florida

  • Advanced Medical Research, PC

    Sandy Springs, Georgia

  • Treasure Valley Medical Research

    Boise, Idaho

  • Sneeze wheeze and Itch Associates LLC

    Normal, Illinois

  • Southern Indiana Clinical Trials

    New Albany, Indiana

  • Visage Clinical Research

    Largo, Maryland

  • Revival Research Corporation- Clinedge

    Troy, Michigan

  • Apex Clinical Research Center

    Painesville, Ohio

  • Clinical Partners, LLC

    Johnston, Rhode Island

  • North Texas Center for Clinical Research

    Frisco, Texas

  • Progressive Clinical Research

    San Antonio, Texas

  • JBR Clinical Research

    Salt Lake City, Utah

  • Dermatology of Seattle & Bellevue

    Seattle, Washington

  • Dermatology Specialists of Spokane

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.